# ILD SOLUTIONS: A New Paradigm in Treating ILD

## KEY TAKEAWAYS



## Non-IPF ILD Can Acquire a Progressive Fibrotic Phenotype

#### **Idiopathic Interstitial Pneumonias**

Idiopathic pulmonary fibrosis Desquamative interstitial pneumonia Cryptogenic organizing pneumonia

#### **Miscellaneous**


Sarcoidosis Eosinophilic pneumonias Pulmonary Langerhans cell histocytois Lymphangioleiomyomatosis

#### **Connective Tissue Disease Related** Systemic sclerosis Rheumatoid arthritis Polymyositis/dermatomyositis


#### **Exposure Related**

Sjogren's syndrome

Drug-induced (amiodarone, nitrofurantoin) Environmental (hypersensitivity pneumonitis) Occupational lung diseases



## Keys to Recognizing Progressive Fibrotic Interstitial Lung Disease (PF-ILD)



#### For more education, please visit www.PILOTforPulmonary.org

## ILD SOLUTIONS: A New Paradigm in Treating ILD

### KEY TAKEAWAYS



## **Newer Treatment Options for PF-ILD**

### Minimally Invasive Lung Transplant (MILT)


MILT was developed by Hannover Medical School in Germany and improved by **Pedro Catarino, MD** (Royal Papworth Hospital, UK now at Cedars-Sinai).

- Reduces likelihood of using cardiopulmonary bypass
- Shorter recovery times
- Good outcomes<sup>1</sup>



Click to watch video describing the first bilateral MILT performed at Cedars-Sinai

### FDA Approves Nintedanib for Treatment of PF-ILD<sup>2</sup>





### References

I. Marczin N,et al . Outcomes of minimally invasive lung transplantation in a single centre: the routine approach for the future or do we still need clamshell incision? Interact Cardiovasc Thorac Surg. 2016 May 1;22(5):537-45. DOI: 10.1093/icvts/ivw004

2. Flaherty KR,et al. Nintedanib in progressive fibrosing interstitial lung diseases. NEJM. 2019 Oct 31;381(18):1718-27. DOI: 10.1056/NEJMoa1908681